GRI Bio, Inc. (GRI)
GRI Bio develops oral drug candidates for lung fibrosis and autoimmune diseases such as lupus. It last closed at $1.33 on Nov 17, down 5.00% on the day. GRI reports earnings on Fri, Jan 29, 2027. The average 12-month price target from 2 analysts is $18.50 (+1291.0% from the last close), with a high of $27.00 and a low of $10.00.
Key Stats
Last 12 monthsNot reported for this period.
From GRI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on GRI in the past 90 days. The average target is $18.50, with a high of $27.00 and a low of $10.00, compared with the last close of $1.33.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 10 | HC Wainwright & Co. | Reiterated | Buy | $10 |
| Aug 24 | Ascendiant Capital | Target lowered | Buy | $32 → $27 |
| Jun 1 | Ascendiant Capital | Maintained | Buy | $32 |
Technical Analysis
The stock is 20% below its 20 day and 30% below its 50 day average. It is 52% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $1.31, and the nearest resistance the Pivot at $1.35.
| RSI (14) | 37.86 | Weak, oversold below 30 | Neutral |
| MACD | -0.02 | Below its signal line | Bearish |
| Stochastic | 21.8 | Middle of its range | Neutral |
| ADX (14) | 17.7 | No clear trend | |
| Williams %R | -100.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -118.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −11.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.15 | Typical daily range, 11.6% of price |
| RSI (14) | 30.47 | Weak, oversold below 30 | Neutral |
| MACD | -2.60 | Above its signal line | Bullish |
| Stochastic | 14.3 | Near the bottom of its range | Oversold |
| ADX (14) | 6.0 | No clear trend | |
| Williams %R | -100.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -95.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −30.0% | Change over 10 sessions | Bearish |
| ATR (14) | $1.62 | Typical daily range, 121.6% of price |
What happened before
See how GRI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GRI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in GRI in the last 90 days.
GRI Institutional Ownership
Full report →- ▼4 buying vs 5 selling
- ▲Held by funds +1.1 pts
- ●Funds holding +0
- ▼Superinvestors: 0 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 11 | 11 | 0.0% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 5.4% | 4.3% | +1.1 pts |
| New / increased | 2 / 2 | 6 / 1 | −42.9% |
| Reduced / sold out | 3 / 2 | 2 / 1 | +66.7% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRI is in one of them and how their past GRI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GRI in an article yet. Here's the latest on the wider market.
About GRI Bio
GRI Bio is a biopharmaceutical company based in La Jolla, California, that is developing oral medicines for diseases driven by an overactive immune system. Its lead candidate, GRI-0621, is being studied for idiopathic pulmonary fibrosis, a progressive disease that scars the lungs. A second candidate, GRI-0803, is in early development for lupus, an autoimmune disease. The company does not yet have any approved products, and its intended patients are people living with these serious conditions.
- Headquarters
- La Jolla, CA
